000075621 001__ 75621
000075621 005__ 20191127155458.0
000075621 0247_ $$2doi$$a10.1038/ajg.2017.501
000075621 0248_ $$2sideral$$a105223
000075621 037__ $$aART-2018-105223
000075621 041__ $$aeng
000075621 100__ $$aChaparro, M.
000075621 245__ $$aLong-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
000075621 260__ $$c2018
000075621 5060_ $$aAccess copy available to the general public$$fUnrestricted
000075621 5203_ $$aOBJECTIVES: The long-term safety of exposure to anti-tumor necrosis factor (anti-TNF alpha) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNF alpha drugs in utero with that of children who were not exposed to the drugs. METHODS: Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNF alpha medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNF alpha agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan-Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring. RESULTS: The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNF alpha agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8-1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5-4.3)). CONCLUSIONS: In utero exposure to anti-TNF alpha drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.
000075621 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI13-00041
000075621 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000075621 590__ $$a10.241$$b2018
000075621 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b7 / 84 = 0.083$$c2018$$dQ1$$eT1
000075621 592__ $$a3.668$$b2018
000075621 593__ $$aHepatology$$c2018$$dQ1
000075621 593__ $$aGastroenterology$$c2018$$dQ1
000075621 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000075621 700__ $$aVerreth, A.
000075621 700__ $$aLobaton, T.
000075621 700__ $$aGravito-Soares, E.
000075621 700__ $$aJulsgaard, M.
000075621 700__ $$aSavarino, E.
000075621 700__ $$aMagro, F.
000075621 700__ $$aBiron, I.A.
000075621 700__ $$aLopez-Serrano, P.
000075621 700__ $$aCasanova, M.J.
000075621 700__ $$aGompertz, M.
000075621 700__ $$aVitor, S.
000075621 700__ $$0(orcid)0000-0002-4991-8715$$aArroyo, M.$$uUniversidad de Zaragoza
000075621 700__ $$aPugliese, D.
000075621 700__ $$aZabana, Y.
000075621 700__ $$aVicente, R.
000075621 700__ $$aAguas, M.
000075621 700__ $$aShitrit, A.B.G.
000075621 700__ $$aGutierrez, A.
000075621 700__ $$aDoherty, G.A.
000075621 700__ $$aFernandez-Salazar, L.
000075621 700__ $$aCadilla, J.M.
000075621 700__ $$aHuguet, J.M.
000075621 700__ $$aO''Toole, A.
000075621 700__ $$aStasi, E.
000075621 700__ $$aMarcos, N.M.
000075621 700__ $$aVilloria, A.
000075621 700__ $$aKarmiris, K.
000075621 700__ $$aRahier, J.F.
000075621 700__ $$aRodriguez, C.
000075621 700__ $$aPalomares, M.D.L.
000075621 700__ $$aFiorino, G.
000075621 700__ $$aBenitez, J.M.
000075621 700__ $$aPrincipi, M.
000075621 700__ $$aNaftali, T.
000075621 700__ $$aTaxonera, C.
000075621 700__ $$aMantzaris, G.
000075621 700__ $$aSebkova, L.
000075621 700__ $$aIade, B.
000075621 700__ $$aLissner, D.
000075621 700__ $$aBradley, I.F.
000075621 700__ $$aRoman, A.L.S.
000075621 700__ $$aMarin-Jimenez, I.
000075621 700__ $$aMerino, O.
000075621 700__ $$aSierra, M.
000075621 700__ $$aVan Domselaar, M.
000075621 700__ $$aCaprioli, F.
000075621 700__ $$aGuerra, I.
000075621 700__ $$aPeixe, P.
000075621 700__ $$aPiqueras, M.
000075621 700__ $$aRodriguez-Lago, I.
000075621 700__ $$aBer, Y.
000075621 700__ $$avan Hoeve, K.
000075621 700__ $$aTorres, P.
000075621 700__ $$aGravito-Soares, M.
000075621 700__ $$aRudbeck-Resdal, D.
000075621 700__ $$aBartolo, O.
000075621 700__ $$aPeixoto, A.
000075621 700__ $$aMartin, G.
000075621 700__ $$aArmuzzi, A.
000075621 700__ $$aGarre, A.
000075621 700__ $$aDonday, M.G.
000075621 700__ $$ade Carpi, F.J.M.
000075621 700__ $$aGisbert, J.P.
000075621 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000075621 773__ $$g113, 3 (2018), 396-403$$pAm. j. gastroenterol.$$tAmerican Journal of Gastroenterology$$x0002-9270
000075621 8564_ $$s301862$$uhttps://zaguan.unizar.es/record/75621/files/texto_completo.pdf$$yPostprint
000075621 8564_ $$s118222$$uhttps://zaguan.unizar.es/record/75621/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000075621 909CO $$ooai:zaguan.unizar.es:75621$$particulos$$pdriver
000075621 951__ $$a2019-11-27-15:48:44
000075621 980__ $$aARTICLE